Small-cell lung cancer and immunochemotherapy with Propionibacterium granulosum KP 45

J Cancer Res Clin Oncol. 1985;109(1):72-7. doi: 10.1007/BF01884258.


Seventy-nine patients with small-cell lung cancer were treated with vincristin, methotrexate, and cyclophosphamide in inductive therapy and with methotrexate, cyclophosphamide, and procarbazine in maintenance therapy. Patients were divided at random into two groups: one group received chemotherapy alone and the second group was additionally subjected to systemic immunotherapy with Propionibacterium granulosum strain KP-45. In general, differences in the frequency of therapy response and in duration of remission could not be stated between the two groups of patients, but patients responding to chemotherapy showed a significantly longer remission time and lower complication rates. This benificial effect of chemoimmunotherapy is not related to a direct antitumor activity of the immunomodifier used, but to the lowered risk of myelosuppression and infections. Immunomodulation in combination with chemo- and/or radiotherapy can be recommended for the treatment of small-cell lung cancer.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Small Cell / mortality
  • Carcinoma, Small Cell / therapy*
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Humans
  • Immunotherapy / methods*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / therapy*
  • Methotrexate / administration & dosage
  • Middle Aged
  • Neoplasm Metastasis
  • Procarbazine / administration & dosage
  • Propionibacterium / immunology*
  • Vincristine / administration & dosage


  • Procarbazine
  • Vincristine
  • Cyclophosphamide
  • Methotrexate